Poster Presentation (Abstract #353): Safety and efficacy of tumor infiltrating lymphocytes (TIL; LN-145) in combination with pembrolizumab for advanced, recurrent or metastatic HNSCC
Authors: A Jimeno, et al.
Dates/Times: Wednesday, Nov. 11, from 5:15-5:45 p.m. EST and Friday, Nov. 13, from 4:40-5:10 p.m. EST
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, will present at the Jefferies Healthcare conference on June 5th.
Panel: Strategies to Optimize and Improve Manufacturing Processes in TIL, CTL and Neoantigen Therapies
Presenter: Joseph Wypych, Vice President of Manufacturing
Date: Wednesday, Dec. 12, 2018
Time: 10 a.m. EST
Presentation: Developing Tumor Infiltrating Lymphocytes for the Treatment of Cancer
Presenter: Maria Fardis, Ph.D., MBA, President and Chief Executive Officer
Date: Thursday, Dec. 13, 2018
Time: 9:10 a.m. EST
The Tumor Targeted Lymphocyte Summit is the first, dedicated meeting that unites the expert community working in TIL and CTL therapies to network, learn and determine strategies to enhance the efficacy of adoptive cell therapy in solid tumors. For additional information, please see http://tumor-targeted-lymphocytes.com.
The Melanoma Poster (#P022, even) is to be displayed on Friday, 09 and Saturday, 10 November:
Poster Hall Location: Hall E
Poster Hall Hours: Friday, Nov. 9 from 8 a.m. – 8 p.m. and Saturday, Nov. 10 from 8 a.m. – 8:30 p.m.
Dr. Sarnaik will be at the poster for 2 intervals on Saturday, Nov. 10 from 12:20 – 1:50 pm and 7:00 – 8:30 pm.
The Oral Presentation will be on Sunday, 11 November in the following session:
Session Information:Session 302
Session: Clinical Trials Session Dates and Times*:Sunday, Nov. 11 from 8:05 – 10:15 a.m. Dr. Sarnaik is first speaker of session starting at 8:10 am “Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients following progression on checkpoint inhibitors” Format: 10 minute long presentation with 5 minutes of Q&A for a total of 15 minutes
A replay is available until 4:30 p.m. ET on May 31, 2017. To access the replay, please dial 1-855-859-2056 (domestic) or 1-404-537-3406 (international) and reference the access code 8895265.
A replay of the call is available until 4:30 p.m. ET on March 17, 2017. To access the replay, please dial 1-855-859-2056 (domestic) or 1-404-537-3406 (international) and reference the access code 75631507.
